final program.qxd - Parallels Plesk Panel

PP 4.18
Rosuvastatin administration for protease inhibitor-related hyperlipidemia, with a
predominant hypercholesterolemic component
Leonardo Calza, Roberto Manfredi
Infectious Diseases, University of Bologna, Italy
Introduction
Lipid-lowering therapy is recommended to HIV-infected patients (p) when protease
inhibitor (PI)-associated hyperlipidemia (often represented by a mixed form of
hypercholesterolemia-hypertriglyceridemia), is severe or persists for a long time despite
diet-physical exercise, but the choice of hypolipidemic drugs is often problematic due to
pharmacological interactions, increased toxicity, and lack of comparative randomized
trials.
Patients and Methods
The aim of our prospective, open-label pilot study was to assess the efficacy and safety
of the novel, potent statin rosuvastatin for the management of HIV-infected p receiving a
PI-based anti-HIV therapy. Selection criteria included p with hypercholesterolemia
persisting for six months or more. P were treated with rosuvastatin (10 mg/day) for 24
weeks, when an interim analysis was performed.
Results
Until now, 25 p were enrolled and followed-up. At the end of the 24-week preliminary
observation period, the median reduction of cholesterol-triglyceride levels versus median
baseline values was 22.1% (range 14.2-32.1%) and 26.9.1% (range 17.8-37.1%),
respectively (p